-
EP2879661
European procedure
Extract from the Register of European Patents
EP About this file: EP2879661
| EP2879661 - INJECTABLE COMPOSITIONS COMPRISING LETROZOLE OR ANASTROZOLE [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 02.12.2022 Database last updated on 01.04.2026 | |
| Former | The patent has been granted Status updated on 24.12.2021 | ||
| Former | Grant of patent is intended Status updated on 22.09.2021 | ||
| Former | Examination is in progress Status updated on 04.08.2017 | Most recent event Tooltip | 09.12.2022 | Change - lapse in a contracting state State(s) deleted from list of lapses: AL | published on 11.01.2023 [2023/02] | Applicant(s) | For all designated states Laboratorios Farmacéuticos Rovi, S.A. C/ Julián Camarillo 35 28037 Madrid / ES | [2015/24] | Inventor(s) | 01 /
FRANCO RODRÍGUEZ, Guillermo C/ Julián Camarillo 35 E-28037 Madrid / ES | 02 /
GUTIERRO ADURIZ, Ibon C/ Julián Camarillo 35 E-28037 Madrid / ES | [2015/24] | Representative(s) | Elzaburu S.L.P. Edificio Torre de Cristal Paseo de la Castellana 259 C, planta 28 28046 Madrid / ES | [2022/04] |
| Former [2015/24] | Elzaburu S.L.P. C/ Miguel Angel, 21 28010 Madrid / ES | Application number, filing date | 13742226.7 | 29.07.2013 | [2022/04] | WO2013EP65877 | Priority number, date | ES20120031271 | 03.08.2012 Original published format: ES 201231271 | [2015/24] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014019972 | Date: | 06.02.2014 | Language: | EN | [2014/06] | Type: | A1 Application with search report | No.: | EP2879661 | Date: | 10.06.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.02.2014 takes the place of the publication of the European patent application. | [2015/24] | Type: | B1 Patent specification | No.: | EP2879661 | Date: | 26.01.2022 | Language: | EN | [2022/04] | Search report(s) | International search report - published on: | EP | 06.02.2014 | Classification | IPC: | A61K9/00, A61P35/00, A61K31/4196, A61K9/10, A61K47/34, A61K47/20 | [2021/41] | CPC: |
A61K31/4196 (EP,ES,KR);
A61K9/0024 (EP,KR);
A61K47/20 (EP,KR);
A61K47/34 (EP,KR);
A61K9/10 (EP,KR);
A61P35/00 (EP,KR);
A61P43/00 (EP)
(-)
|
| Former IPC [2015/24] | A61K9/00, A61K47/20, A61K47/34, A61K9/10, A61K31/4196 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/24] | Extension states | BA | 26.02.2015 | ME | 26.02.2015 | Title | German: | INJIZIERBARE ZUSAMMENSETZUNGEN MIT LETROZOL ODER ANASTROZOL | [2015/24] | English: | INJECTABLE COMPOSITIONS COMPRISING LETROZOLE OR ANASTROZOLE | [2015/24] | French: | COMPOSITIONS INJECTABLES COMPRENANT DU LÉTROZOLE OU DE L'ANASTROZOLE | [2015/24] | Entry into regional phase | 26.02.2015 | National basic fee paid | 26.02.2015 | Designation fee(s) paid | 26.02.2015 | Examination fee paid | Examination procedure | 26.02.2015 | Examination requested [2015/24] | 11.09.2015 | Amendment by applicant (claims and/or description) | 02.08.2017 | Despatch of a communication from the examining division (Time limit: M04) | 05.12.2017 | Reply to a communication from the examining division | 21.02.2019 | Despatch of a communication from the examining division (Time limit: M06) | 03.09.2019 | Reply to a communication from the examining division | 22.06.2020 | Despatch of a communication from the examining division (Time limit: M06) | 02.02.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 31.03.2021 | Reply to a communication from the examining division | 12.05.2021 | Despatch of a communication from the examining division (Time limit: M04) | 23.07.2021 | Reply to a communication from the examining division | 23.09.2021 | Communication of intention to grant the patent | 20.12.2021 | Fee for grant paid | 20.12.2021 | Fee for publishing/printing paid | 20.12.2021 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 02.08.2017 | Opposition(s) | 27.10.2022 | No opposition filed within time limit [2023/01] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 31.03.2021 | Request for further processing filed | 31.03.2021 | Full payment received (date of receipt of payment) Request granted | 13.04.2021 | Decision despatched | Fees paid | Renewal fee | 10.07.2015 | Renewal fee patent year 03 | 29.06.2016 | Renewal fee patent year 04 | 14.07.2017 | Renewal fee patent year 05 | 27.07.2018 | Renewal fee patent year 06 | 21.06.2019 | Renewal fee patent year 07 | 07.07.2020 | Renewal fee patent year 08 | 28.06.2021 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | deleted | [2023/02] |
| Former [2023/01] | AL | 26.01.2022 | Cited in | International search | [XI] EP2394663 (ROVI LAB FARMACEUT SA et al.) | [A] WO2009060473 (PANACEA BIOTEC LTD et al.) | by applicant | WO2008041245 | WO2010065358 | WO2012074883 | US2008206303 |